Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases.

Cancers (Basel) · 2025 · PMC11988070 · PMID 40227676

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The cumulative incidence of aGvHD at day +100 was numerically different in the Flu/Bu4 group and Flu/Bu4/TBI group (grade II–IV, 29.2% versus 63.6%, p < 0.1; grade III–IV, 8.3% versus 13.6, p = 0.7), though these findings did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.